Mediez Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.17 M
- Company Age 24 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.00 M
- Revenue Growth 6.86%
- Profit Growth 75.10%
- Ebitda 173.39%
- Net Worth 27.82%
- Total Assets 0.83%
About Mediez Pharma
Mediez Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 September 2000 and has a history of 24 years and four months. Its registered office is in Sirsa, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.17 M.
The company has closed loans amounting to ₹2.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anil Goyal and Akhilesh Kumar serve as directors at the Company.
Company Details
-
Location
Sirsa, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239HR2000PTC034553
-
Company No.
034553
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Sep 2000
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Mediez Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Goyal
|
Director | 25-Sep-2000 | Current |
|
Akhilesh Kumar
|
Director | 29-Jan-2010 | Current |
Financial Performance of Mediez Pharma.
Mediez Pharma Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 6.86% increase. The company also saw a substantial improvement in profitability, with a 75.1% increase in profit. The company's net worth Soared by an impressive increase of 27.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mediez Pharma?
In 2019, Mediez Pharma had a promoter holding of 65.48% and a public holding of 34.52%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Mediez Solar Energy Private LimitedAnil Goyal is a mutual person
Charges (Loans)
₹0
₹2.00 M
Charges Breakdown by Lending Institutions
- Indian Bank : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Apr 2010 | Indian Bank | ₹2.00 M | Satisfied |
How Many Employees Work at Mediez Pharma?
Unlock and access historical data on people associated with Mediez Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediez Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediez Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
